Miami-based OPKO Health, Inc. has established itself as a key player in the healthcare industry. The company operates in the diagnostics and pharmaceutical sectors in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. Its Diagnostics business segment, which runs BioReference Laboratories, provides laboratory testing services for various diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. In addition, the segment also offers a cutting-edge diagnostic instrument system, as well as 4Kscore prostate cancer testing services. OPKO Health's pharmaceutical division, on the other hand, boasts a suite of drugs designed to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, vitamin D insufficiency, and type 2 diabetes and associated obesity. The company has also developed longer-acting proprietary versions of already approved therapeutic proteins, such as a once-weekly human growth hormone injection that completed Phase III clinical trial in collaboration with Pfizer, Inc. Additionally, OPKO Health offers specialty APIs, pharmaceutical, nutraceutical, veterinary, and ophthalmic products, and commercializes food supplements and over the counter products. Moreover, the company imports, markets, distributes, and sells pharmaceutical products across various indications. Overall, OPKO Health has diversified its portfolio and built a robust presence in multiple locations worldwide. The company was founded in 1991 and has continued to expand its operations since then, cementing its status as a leading healthcare provider.
OPKO Health's ticker is OPK
The company's shares trade on the NYSE stock exchange
They are based in Miami, Florida
There are 501-1000 employees working at OPKO Health
It is opko.com
OPKO Health is in the Healthcare sector
OPKO Health is in the Biotechnology industry
The following five companies are OPKO Health's industry peers: